Overview Financials News + Filings Key Docs Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results
|
Nautilus Biotechnology, Inc.
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
06/16/2023 |
4
| McIlwain Matthew S (Director) has filed a Form 4 on Nautilus Biotechnology, Inc.
Txns:
| Granted 45,000 options to buy
@ $3.97, valued at
$178.7k
|
|
06/16/2023 |
4
| Posard Matthew L. (Director) has filed a Form 4 on Nautilus Biotechnology, Inc.
Txns:
| Granted 45,000 options to buy
@ $3.97, valued at
$178.7k
|
|
06/16/2023 |
4
| Pande Vijay Satyanand (Director) has filed a Form 4 on Nautilus Biotechnology, Inc.
Txns:
| Granted 45,000 options to buy
@ $3.97, valued at
$178.7k
|
|
06/16/2023 |
4
| Epperly Melissa B, (Director) has filed a Form 4 on Nautilus Biotechnology, Inc.
Txns:
| Granted 45,000 options to buy
@ $3.97, valued at
$178.7k
|
|
06/16/2023 |
4
| NAZEM FARZAD (Director) has filed a Form 4 on Nautilus Biotechnology, Inc.
Txns:
| Granted 45,000 options to buy
@ $3.97, valued at
$178.7k
|
|
06/16/2023 |
4
| Akinsanya Karen (Director) has filed a Form 4 on Nautilus Biotechnology, Inc.
Txns:
| Granted 45,000 options to buy
@ $3.97, valued at
$178.7k
|
|
03/01/2023 |
4
| Patel Sujal M (CEO, President, and Secretary) has filed a Form 4 on Nautilus Biotechnology, Inc.
Txns:
| Granted 650,000 options to buy
@ $2, valued at
$1.3M
|
|
03/01/2023 |
4
| Mowry Anna (CFO and Treasurer) has filed a Form 4 on Nautilus Biotechnology, Inc.
Txns:
| Granted 160,000 options to buy
@ $2, valued at
$320k
|
|
03/01/2023 |
4
| Murphy Matthew B. (General Counsel) has filed a Form 4 on Nautilus Biotechnology, Inc.
Txns:
| Granted 160,000 options to buy
@ $2, valued at
$320k
|
|
03/01/2023 |
4
| Godwin Mary E. (Senior VP, Operations) has filed a Form 4 on Nautilus Biotechnology, Inc.
Txns:
| Granted 160,000 options to buy
@ $2, valued at
$320k
|
|
03/01/2023 |
4
| Mallick Parag (Chief Scientist) has filed a Form 4 on Nautilus Biotechnology, Inc.
Txns:
| Granted 280,000 options to buy
@ $2, valued at
$560k
|
|
03/01/2023 |
4
| Weld Gwen E (Chief People Officer) has filed a Form 4 on Nautilus Biotechnology, Inc.
Txns:
| Granted 160,000 options to buy
@ $2, valued at
$320k
|
|
03/01/2023 |
4
| Nelson Nicholas A. (CBO & Senior VP, Bus. Dev.) has filed a Form 4 on Nautilus Biotechnology, Inc.
Txns:
| Granted 160,000 options to buy
@ $2, valued at
$320k
|
|
03/01/2023 |
4
| Sankar Subramanian (Senior VP, Product Development) has filed a Form 4 on Nautilus Biotechnology, Inc.
Txns:
| Granted 160,000 options to buy
@ $2, valued at
$320k
|
|
09/28/2022 |
4
| Sankar Subramanian (Senior VP, Product Development) has filed a Form 4 on Nautilus Biotechnology, Inc.
Txns:
| Bought 10,000 shares
@ $2.025, valued at
$20.3k
Bought 5,000 shares
@ $2.0298, valued at
$10.1k
|
|
09/26/2022 |
4
| Weld Gwen E (Chief People Officer) has filed a Form 4 on Nautilus Biotechnology, Inc.
Txns:
| Bought 30,000 shares
@ $2.0255, valued at
$60.8k
|
|
09/19/2022 |
4
| Sankar Subramanian (Senior VP, Product Development) has filed a Form 4 on Nautilus Biotechnology, Inc.
Txns:
| Bought 40,000 shares
@ $2.1938, valued at
$87.8k
Bought 35,000 shares
@ $2.1556, valued at
$75.4k
|
|
08/22/2022 |
4
| Mowry Anna (CFO and Treasurer) has filed a Form 4 on Nautilus Biotechnology, Inc.
Txns:
| Bought 17,500 shares
@ $2.2982, valued at
$40.2k
|
|
08/16/2022 |
4
| Murphy Matthew B. (General Counsel) has filed a Form 4 on Nautilus Biotechnology, Inc.
Txns:
| Bought 2,500 shares
@ $2.85, valued at
$7.1k
Bought 7,500 shares
@ $2.841, valued at
$21.3k
|
|
08/08/2022 |
4
| Patel Sujal M (CEO, President, and Secretary) has filed a Form 4 on Nautilus Biotechnology, Inc.
Txns:
| Bought 41,654 shares
@ $2.9204, valued at
$121.6k
Bought 8,346 shares
@ $2.9288, valued at
$24.4k
|
|
08/03/2022 |
4
| Godwin Mary E. (Senior VP, Operations) has filed a Form 4 on Nautilus Biotechnology, Inc.
Txns:
| Granted 30,000 options to buy
@ $2.83, valued at
$84.9k
|
|
07/01/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
06/28/2022 |
4
| Mowry Anna (CFO and Treasurer) has filed a Form 4 on Nautilus Biotechnology, Inc.
Txns:
| Bought 5,500 shares
@ $2.7499, valued at
$15.1k
|
|
06/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/16/2022 |
4
| NAZEM FARZAD (Director) has filed a Form 4 on Nautilus Biotechnology, Inc.
Txns:
| Granted 86,467 options to buy
@ $2.7, valued at
$233.5k
|
|
06/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/16/2022 |
4
| Pande Vijay Satyanand (Director) has filed a Form 4 on Nautilus Biotechnology, Inc.
Txns:
| Granted 86,467 options to buy
@ $2.7, valued at
$233.5k
|
|
05/13/2022 |
4
| Murphy Matthew B. (General Counsel) has filed a Form 4 on Nautilus Biotechnology, Inc.
Txns:
| Granted 10,000 shares
@ $3.28, valued at
$32.8k
|
|
05/10/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/05/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|
|
|